WO2014026372A1 - 用于抑制运动神经元自体吞噬的医药组合物及其应用 - Google Patents
用于抑制运动神经元自体吞噬的医药组合物及其应用 Download PDFInfo
- Publication number
- WO2014026372A1 WO2014026372A1 PCT/CN2012/080291 CN2012080291W WO2014026372A1 WO 2014026372 A1 WO2014026372 A1 WO 2014026372A1 CN 2012080291 W CN2012080291 W CN 2012080291W WO 2014026372 A1 WO2014026372 A1 WO 2014026372A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- compound
- formula
- composition according
- motor neurons
- Prior art date
Links
- QOGDUZDAPVKBAN-GDVGLLTNSA-N CCC(CC1)[C@H]1N Chemical compound CCC(CC1)[C@H]1N QOGDUZDAPVKBAN-GDVGLLTNSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Definitions
- the present invention relates to a pharmaceutical composition for inhibiting autophagy of motor neurons and uses thereof, and more particularly to a pharmaceutical composition for delaying the onset of motor neuron degenerative diseases and/or treating motor neurodegenerative diseases And its applications.
- Neurons also called nerve cells, are one of the structural and functional units of the nervous system of the organism. They can transmit information to other cells by means of chemical signals and electrical signals. They can be of various shapes and sizes, and the diameter can be From about 4 microns to about 100 microns, the structure can be roughly divided into three parts: the cell body, the dendrite, and the axon. The dendrites can bring information into the cell body, while the axons can The message is transmitted from the cell body.
- Neurons can be distinguished into three types according to their message transmission direction and function: sensory neuron, motor neuron, and interneuron, in which motor neurons are nerve cells that control the activity of living organisms. .
- motor neurons in the brain are called upper motor neurons, while motor neurons in the brainstem and spinal cord are called lower motor neurons.
- motor neuron degeneration causes dysfunction, it may cause amyotrophic lateral sclerosis (ALS), myasthenia gravis, muscle weakness, muscle atrophy, muscular dystrophy, multiple sclerosis ( Multiple sclerosis), multiple system atrophy, spinal muscular dystrophy, and other motor neurodegenerative diseases.
- ALS amyotrophic lateral sclerosis
- MERS multiple sclerosis
- multiple system atrophy spinal muscular dystrophy
- spinal muscular dystrophy and other motor neurodegenerative diseases.
- the body gradually develops symptoms such as muscle weakness, atrophy, tremors, convulsions, stiffness, and may cause difficulty in pronunciation, difficulty in swallowing, and respiratory failure.
- Y is O or S, and may form a five-membered ring with A bond as needed;
- Figure 1A is a mass spectrum of a sample prepared by mixing a mixture of butylene phenol and human liver microsomes by liquid chromatography tandem mass spectrometry;
- Figure 3 is a graph showing the survival curve of the survival rate of SOD1 G93A transgenic mice by sharp force;
- Fig. 4 is a survival curve of the BBB score of the SOD1 G93A transgenic mice affected by butylene phenol;
- Figure 5B is a bar graph of butylenebene phenol delaying or avoiding death of spinal motor neurons in SOD1 G93A transgenic mice;
- Figure 6 is a photograph of a western blot of the amount of LC3-II protein in the lumbar tissue of SOD1 G93A transgenic mice by p-butylene phenol;
- NSC neural stem cell
- the NSC cells were cultured in a 10 cm diameter culture dish. After the cells proliferated to about six minutes, the cells were washed with phosphate buffered saline (PBS), and then treated with different concentrations of butylene phenol for 12 hours. Hydrogen peroxide (2500 micromolar milliliters) was treated for 12 hours to stimulate the cells for autophagy.
- PBS phosphate buffered saline
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112015001989-7A BR112015001989B1 (pt) | 2012-08-17 | 2012-08-17 | Uso de butilidenoftalida (bp) |
NZ703195A NZ703195B2 (en) | 2012-08-17 | Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof | |
KR1020157000505A KR101695801B1 (ko) | 2012-08-17 | 2012-08-17 | 운동 뉴런의 자가 포식 작용 억제를 위한 약학적 조성물 및 이의 용도 |
JP2014555922A JP6178802B2 (ja) | 2012-08-17 | 2012-08-17 | 運動ニューロンのオートファジーを阻害するための医薬組成物およびその使用 |
AU2012387970A AU2012387970B2 (en) | 2012-08-17 | 2012-08-17 | Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof |
ES12883034.6T ES2655834T3 (es) | 2012-08-17 | 2012-08-17 | Composición farmacéutica para inhibir la autofagia de las neuronas motoras y uso de la misma |
RU2015102728/15A RU2585372C1 (ru) | 2012-08-17 | 2012-08-17 | Фармацевтическая композиция для ингибирования аутофагии двигательных нейронов и её применение |
EP12883034.6A EP2992879B1 (en) | 2012-08-17 | 2012-08-17 | Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof |
PCT/CN2012/080291 WO2014026372A1 (zh) | 2012-08-17 | 2012-08-17 | 用于抑制运动神经元自体吞噬的医药组合物及其应用 |
MYPI2015700018A MY180932A (en) | 2012-08-17 | 2012-08-17 | Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof |
PH12015500047A PH12015500047A1 (en) | 2012-08-17 | 2015-01-08 | Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/080291 WO2014026372A1 (zh) | 2012-08-17 | 2012-08-17 | 用于抑制运动神经元自体吞噬的医药组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014026372A1 true WO2014026372A1 (zh) | 2014-02-20 |
Family
ID=50101210
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/080291 WO2014026372A1 (zh) | 2012-08-17 | 2012-08-17 | 用于抑制运动神经元自体吞噬的医药组合物及其应用 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2992879B1 (zh) |
JP (1) | JP6178802B2 (zh) |
KR (1) | KR101695801B1 (zh) |
AU (1) | AU2012387970B2 (zh) |
BR (1) | BR112015001989B1 (zh) |
ES (1) | ES2655834T3 (zh) |
PH (1) | PH12015500047A1 (zh) |
RU (1) | RU2585372C1 (zh) |
WO (1) | WO2014026372A1 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017521417A (ja) * | 2014-07-04 | 2017-08-03 | 長弘生物科技股▲ふん▼有限公司 | フタリド化合物の使用 |
US9889117B2 (en) | 2014-07-02 | 2018-02-13 | Everfront Biotech Inc. | Method for treating and/or delaying the degeneration of Purkinje cells |
US11369595B2 (en) | 2016-09-05 | 2022-06-28 | Metabrain Research | Use of tryptophan metabolites for treating muscle atrophy |
US11801284B2 (en) | 2017-12-13 | 2023-10-31 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating motor neuron diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101184484B (zh) * | 2005-05-24 | 2011-10-05 | 帝斯曼知识产权资产管理有限公司 | 用于治疗炎性失调的藁本内酯衍生物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05247022A (ja) * | 1990-07-10 | 1993-09-24 | Tsumura & Co | 新規フタリドおよびフタリドを有効成分とする脳機能改善剤 |
WO2002060234A2 (en) * | 2000-11-22 | 2002-08-08 | Yong Chao Xia | Herbal composition for treatment of neuronal injuries and neuronal degeneration, methods to prepare the same and uses thereof |
KR20090078777A (ko) * | 2006-08-11 | 2009-07-20 | 디에스엠 아이피 어셋츠 비.브이. | 중추 신경계 질환의 치료를 위한 리구스틸라이드 유도체 |
TWI331033B (en) * | 2007-04-26 | 2010-10-01 | Yangsen Biotechnology Co Ltd | Composition for inhibiting no and/or prostaglandin e2 synthesis and uses thereof |
-
2012
- 2012-08-17 BR BR112015001989-7A patent/BR112015001989B1/pt active IP Right Grant
- 2012-08-17 AU AU2012387970A patent/AU2012387970B2/en active Active
- 2012-08-17 WO PCT/CN2012/080291 patent/WO2014026372A1/zh active Application Filing
- 2012-08-17 ES ES12883034.6T patent/ES2655834T3/es active Active
- 2012-08-17 JP JP2014555922A patent/JP6178802B2/ja active Active
- 2012-08-17 RU RU2015102728/15A patent/RU2585372C1/ru active
- 2012-08-17 EP EP12883034.6A patent/EP2992879B1/en active Active
- 2012-08-17 KR KR1020157000505A patent/KR101695801B1/ko active IP Right Grant
-
2015
- 2015-01-08 PH PH12015500047A patent/PH12015500047A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101184484B (zh) * | 2005-05-24 | 2011-10-05 | 帝斯曼知识产权资产管理有限公司 | 用于治疗炎性失调的藁本内酯衍生物 |
Non-Patent Citations (2)
Title |
---|
AMYOTROPHIC LATERAL SCLEROSIS, vol. 10, 2009, pages 85 - 94 |
See also references of EP2992879A4 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9889117B2 (en) | 2014-07-02 | 2018-02-13 | Everfront Biotech Inc. | Method for treating and/or delaying the degeneration of Purkinje cells |
JP2017521417A (ja) * | 2014-07-04 | 2017-08-03 | 長弘生物科技股▲ふん▼有限公司 | フタリド化合物の使用 |
US11369595B2 (en) | 2016-09-05 | 2022-06-28 | Metabrain Research | Use of tryptophan metabolites for treating muscle atrophy |
US11801284B2 (en) | 2017-12-13 | 2023-10-31 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating motor neuron diseases |
Also Published As
Publication number | Publication date |
---|---|
RU2585372C1 (ru) | 2016-05-27 |
KR20150043288A (ko) | 2015-04-22 |
JP2015506963A (ja) | 2015-03-05 |
AU2012387970B2 (en) | 2015-10-29 |
BR112015001989B1 (pt) | 2022-06-14 |
PH12015500047B1 (en) | 2015-03-02 |
NZ703195A (en) | 2016-06-24 |
JP6178802B2 (ja) | 2017-08-09 |
ES2655834T3 (es) | 2018-02-21 |
BR112015001989A2 (pt) | 2017-07-04 |
KR101695801B1 (ko) | 2017-01-13 |
EP2992879B1 (en) | 2017-12-06 |
BR112015001989A8 (pt) | 2018-03-06 |
AU2012387970A1 (en) | 2015-01-22 |
PH12015500047A1 (en) | 2015-03-02 |
EP2992879A4 (en) | 2016-05-11 |
EP2992879A1 (en) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6876047B2 (ja) | ミトコンドリアの活性酸素種(ros)産生に関連する疾患の治療のための化合物 | |
US20160287531A1 (en) | Therapeutic agents for skin diseases and conditions | |
JP2022523864A (ja) | ニコチンアミドリボシドのリン誘導体を含む組成物及びニコチンアミドアデニンジヌクレオチドのモジュレーションのための方法 | |
WO2014026372A1 (zh) | 用于抑制运动神经元自体吞噬的医药组合物及其应用 | |
TW202207928A (zh) | 肝病之組合治療 | |
JP2023087054A (ja) | ミトコンドリア障害を処置するための方法 | |
TWI460168B (zh) | 用於抑制運動神經元自體吞噬之醫藥組合物及其應用 | |
WO2014139318A1 (zh) | 苯酞化合物的应用 | |
JP2002507211A (ja) | ジヒドロホノキオール組成物の合成 | |
US11013716B2 (en) | Method for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, CXC chemokine receptor 4, and/or immune regulatory factor of stem cell | |
US20160024118A1 (en) | Copper (i) complexes with glycine, pyruvate, and succinate | |
KR101297763B1 (ko) | 알츠하이머 병 치료용 의약의 제조를 위한 s-아데노실메티오닌(sam) 및 슈퍼옥시드 디스뮤타아제(sod)의 용도 | |
US20190216880A1 (en) | Composition for topical use based on a carnosine-magnesium complex | |
NZ703195B2 (en) | Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof | |
US10918641B2 (en) | Use of MTAP inhibitors for the treatment of lung disease | |
US20130131361A1 (en) | Novel medical application of lipid derivatives of dopamine and the methods of their production | |
EP2324824B1 (en) | Medical application of a lipid derivative of dopamine | |
US20230390226A1 (en) | Intranasal administration of suramin for treating nervous system disorders | |
JP6413008B2 (ja) | フタリド化合物の使用 | |
WO2022140279A1 (en) | Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12883034 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012883034 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014555922 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20157000505 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12015500047 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2012387970 Country of ref document: AU Date of ref document: 20120817 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2015102728 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015001989 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015001989 Country of ref document: BR Kind code of ref document: A2 Effective date: 20150128 |